Silexion Therapeutics Corp, a Cayman Islands-based company, announced on May 22, 2025, that it received a delisting notice from the Nasdaq Listing Qualifications Department. The notice pertains to the company's failure to comply with Nasdaq Listing Rules 5450(b)(2)$(A)$ and 5450(b)(2)$(C)$, which require maintaining a minimum Market Value of Listed Securities of $50 million and a Market Value of Publicly Held Shares of $15 million. Despite a 180-day compliance period ending May 19, 2025, Silexion was unable to rectify these deficiencies. The company plans to appeal the decision before the Nasdaq Hearings Panel by May 29, 2025. If the appeal is unsuccessful, trading of its shares and warrants will be suspended on June 2, 2025, and a Form 25-NSE will be filed with the SEC to remove its securities from Nasdaq listing. Additionally, Silexion intends to apply for a transfer to the Nasdaq Capital Market, contingent upon meeting the required Equity Standard.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.